Transfusion-Dependent β-Thalassemia (TDT) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032


 β-thalassemia are monogenic disorders usually caused by reduced or absent synthesis of the βglobin chain, one of the main components of adult hemoglobin (HbA, α2β2. This results in a relative increase in the unattached αglobin chains (α/β-chain imbalance) that form insoluble Hemi-chromes in the erythrocyte progenitors. The Hemi-chromes damage the erythrocyte membrane, leading to severe intramedullary erythrocyte apoptosis (ineffective erythropoiesis, IE) and severely shortened red blood cell (RBC) life span due to extra-medullary hemolysis, leading to severe anemia.

·       Transfusion-dependent β-thalassemia (TDT) is the most severe form of the disease, characterized by severe anemia, and requires lifelong, regular blood transfusions to maintain Hb levels. These transfusions carry the risk of progressive multi-organ damage due to unavoidable iron overload.

·       In the USA, the estimated β-thalassemia cases range between 1.5 to 2.6 cases per 100,000 population. However, it varies based on geographic presence.

Thelansis’s “Transfusion-Dependent β-Thalassemia (TDT) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Transfusion-Dependent β-Thalassemia (TDT) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

KOLs insights of Transfusion-Dependent β-Thalassemia (TDT) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Transfusion-Dependent β-Thalassemia (TDT) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Transfusion-Dependent β-Thalassemia (TDT) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032

Comments

Popular posts from this blog

Acne Vulgaris – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Herpes Simplex Virus (HSV) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

HR+/HER2- Breast Cancer – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033